The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.125
Bid: 8.00
Ask: 8.25
Change: 0.00 (0.00%)
Spread: 0.25 (3.125%)
Open: 8.125
High: 8.125
Low: 8.125
Prev. Close: 8.125
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New contract for imaging clinical trial services

5 Jul 2017 07:00

RNS Number : 1251K
IXICO plc
05 July 2017
 

5 July 2017

 

IXICO plc

("IXICO" or the "Company")

 

IXICO signs new contract for specialist imaging clinical trial services

 

Expansion of customer base, and endorsement of IXICO's expertise in providing both PET and MR imaging services in neuroscience clinical trials

 

IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed a new contract for specialist imaging clinical trial services. The contract is for a Phase II clinical trial of patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD). Sponsored by specialist Spanish biotech company Araclon Biotech, a Grifols company, this phase II of the study is designed to establish the dosage regimen for the therapy, as well as confirm the treatment safety and tolerability data obtained in phase I.

 

Using our TrialTracker™ digital platform, IXICO will collate both PET and MRI scans acquired at specialist imaging centres across Europe. This data will be then analysed using IXICO's patent protected image analysis technology, which has been customised to evaluate patient eligibility, assess target engagement and quantify drug effects in AD patients.

 

Giulio Cerroni, Chief Executive of IXICO, commented: "We are delighted to be working with Araclon Biotech which continues our success in providing our customers with a solution that spans both PET and MR imaging services. It is a great example of IXICO's growing value to the biopharmaceutical industry and reinforces our confidence in revenue growth this financial year."

 

Manuel Sarasa, Chief Scientific Officer of Araclon, commented: "It is an important milestone for us to initiate phase II of clinical trials for our Azheimer´s vaccine -ABvac40- after receiving approval from the Spanish Agency of Medicinal Products and Medical Service. We are a little closer to achieving our goal, so it is fundamental for us to incorporate the best-in-class suppliers, such as IXICO, to work together in this amazing project that is also supported by some Spanish institutions such as the Zaragoza University."

 

For further information please contact:

IXICO plc

Giulio Cerroni, Chief Executive Officer

Susan Lowther, Chief Financial Officer

 

Tel: +44 20 3763 7499

 

 

Shore Capital (Nomad and Broker)

Bidhi Bhoma / Edward Mansfield/James Wolfe

Tel: +44 20 7408 4090

 

 

FTI Consulting Limited (Investor Relations)

Simon Conway / Mo Noonan

Tel: +44 20 3727 1000

 

 

About IXICO

IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

 

About Araclon Biotech

Araclon Biotech is a Grifols company specializes in researching and developing therapies and diagnostic methods for Alzheimer's disease (AD) and other neurodegenerative diseases. The company, in which Grifols holds a majority stake, focuses on two research areas: the early diagnosis of AD by means of detecting amyloid-beta peptides in the blood, and the treatment of the disease using immunotherapy (vaccines).

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTDMGGNVDRGNZM
Date   Source Headline
7th Jan 20217:00 amRNSIssue of Equity
24th Dec 20207:00 amRNSIXICO secures new contract for £3.4 million
14th Dec 202011:54 amRNSHolding(s) in Company
8th Dec 20207:00 amRNSIXICO contract with new large global pharma
3rd Dec 20202:06 pmRNSSecond Price Monitoring Extn
3rd Dec 20202:01 pmRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSFinancial Results for the year ended 30 Sept 2020
27th Nov 20207:00 amRNSIXICO announces £1.9 million new study award
9th Nov 20207:00 amRNSNotice of Results
3rd Nov 20207:00 amRNSAdditional Alzheimer’s disease contracts
22nd Oct 20207:00 amRNSFurther Huntington’s disease contracts
19th Oct 20207:00 amRNSIXICO to Present at SCA & ARCA Global Conference
19th Oct 20207:00 amRNSTrading Update for year ended 30 September 2020
16th Oct 20207:00 amRNSIXICO and NYU Langone Health sign agreement
30th Sep 20202:05 pmRNSSecond Price Monitoring Extn
30th Sep 20202:00 pmRNSPrice Monitoring Extension
29th Sep 20207:00 amRNS>£2m contract extension win - Huntington’s disease
24th Sep 20207:00 amRNSCollaboration with TRACK-FA NeuroimagingConsortium
21st Sep 20207:00 amRNSIXICO selected to support Alzheimer’s trial
11th Sep 202010:36 amRNSHolding(s) in Company
26th Aug 202011:55 amRNSInvestor presentation
24th Aug 20209:05 amRNSSecond Price Monitoring Extn
24th Aug 20209:00 amRNSPrice Monitoring Extension
24th Aug 20207:00 amRNSTrading Update
13th Aug 20207:00 amRNSInvestor Presentation
8th Jul 20207:00 amRNSConference attendance - On Helix Digital
6th Jul 20207:00 amRNSGrant of share options
24th Jun 20207:00 amRNSTrading Update
20th May 20207:00 amRNSHalf yearly report to 31 March 2020
12th May 20207:00 amRNSNotice of Results
20th Apr 20207:00 amRNSTrading update for H1 2020
14th Apr 20207:00 amRNS£10.5m contract win, update on trading & COVID-19
16th Mar 20209:00 amRNSIXICO announces expanded contract with Vaccinex
2nd Mar 202011:05 amRNSSecond Price Monitoring Extn
2nd Mar 202011:00 amRNSPrice Monitoring Extension
26th Feb 202011:05 amRNSSecond Price Monitoring Extn
26th Feb 202011:00 amRNSPrice Monitoring Extension
19th Feb 20209:00 amRNSIXICO to Present AI Segmentation Research
17th Feb 20204:40 pmRNSSecond Price Monitoring Extn
17th Feb 20204:35 pmRNSPrice Monitoring Extension
17th Feb 20202:05 pmRNSSecond Price Monitoring Extn
17th Feb 20202:00 pmRNSPrice Monitoring Extension
11th Feb 20207:00 amRNSHolding(s) in Company
10th Feb 20209:11 amRNSIXICO to Present at Innovation Forum
3rd Feb 20209:00 amRNSIXICO Supports the AD Neuroimaging Initiative
23rd Jan 20207:00 amRNSDirector/PDMR Shareholding
17th Jan 20204:34 pmRNSResult of AGM
15th Jan 202010:32 amRNSDirector/PDMR Shareholding
13th Jan 20201:29 pmRNSIssue of Equity
23rd Dec 20197:00 amRNSIXICO announces updates to client contracts

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.